genprowebdirectory
Facebook
Linkedin
RSS
Twitter
Youtube
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Search
Facebook
Linkedin
RSS
Twitter
Youtube
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
GEN – Genetic Engineering and Biotechnology News
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Home
2018
AVEO Pharmaceuticals
Cancer
Novartis, Aveo Spar as Exclusive Antibody Deal Ends
Cancer
AVEO Oncology Licenses Tivozanib in Russia and Ukraine
A-Lists
26 Companies at Risk for Delisting
News
Aveo Terminates Cambridge, MA Lease, Takes Out $10M Loan
Cancer
FDA Rejects Aveo’s Tivozanib for RCC; Rips Phase III Results
Cancer
Phase III Results Lead Aveo and Astellas to Plan Regulatory Submissions for Tivozanib
News
IPOs in 2012
Insights
What Does It Take to Swing the IPO Window Open for Biotechs?
Insights
Q1 2011 Closes with a Sense of Optimism
Cancer
Astellas Gains Ex-Asia Rights to Aveo’s Phase III Cancer Drug
1
2
3
Page 1 of 3
Scroll Up
Scroll Up
